Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial

. 2016 Jan ; 65 (1) : 47-56. [epub] 20141125

Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid25425655

OBJECTIVE: This 1-year study aimed to assess low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis. DESIGN: A prospective, randomised, placebo-controlled study beginning with an 8-week open-label induction phase in which patients with histologically confirmed active collagenous colitis received budesonide (Budenofalk, 9 mg/day initially, tapered to 4.5 mg/day), after which 92 patients in clinical remission were randomised to budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days) or placebo in a 12-month double-blind phase with 6 months treatment-free follow-up. Primary endpoint was clinical remission throughout the double-blind phase. RESULTS: Clinical remission during open-label treatment was achieved by 84.5% (93/110 patients). The median time to remission was 10.5 days (95% CI (9.0 to 14.0 days)). The maintenance of clinical remission at 1 year was achieved by 61.4% (27/44 patients) in the budesonide group versus 16.7% (8/48 patients) receiving placebo (treatment difference 44.5% in favour of budesonide; 95% CI (26.9% to 62.7%), p<0.001). Health-related quality of life was maintained during the 12-month double-blind phase in budesonide-treated patients. During treatment-free follow-up, 82.1% (23/28 patients) formerly receiving budesonide relapsed after study drug discontinuation. Low-dose budesonide over 1 year resulted in few suspected adverse drug reactions (7/44 patients), all non-serious. CONCLUSIONS: Budesonide at a mean dose of 4.5 mg/day maintained clinical remission for at least 1 year in the majority of patients with collagenous colitis and preserved health-related quality of life without safety concerns. Treatment extension with low-dose budesonide beyond 1 year may be beneficial given the high relapse rate after budesonide discontinuation. TRIAL REGISTRATION NUMBERS: http://www.clinicaltrials.gov (NCT01278082) and http://www.clinicaltrialsregister.eu (EudraCT: 2007-001315-31).

Zobrazit více v PubMed

Münch A, Aust D, Bohr J, et al. . Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis 2012;6:932–45. PubMed

Hjortswang H, Tysk C, Bohr J, et al. . Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis 2011;43:102–9. PubMed

Baert F, Schmit A, D'Haens G, et al. . Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002;122:20–5. PubMed

Bonderup OK, Hansen JB, Birket-Smith L, et al. . Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 2003;52:248–51. PubMed PMC

Bonderup OK, Hansen JB, Teglbjaerg PS, et al. . Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009;58:68–72. PubMed

Miehlke S, Heymer P, Bethke B, et al. . Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123:978–4. PubMed

Miehlke S, Madisch A, Bethke B, et al. . Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008;135:1510–16. PubMed

Miehlke S, Madisch A, Kupcinskas L, et al. . Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146:1222–30.e2. PubMed

Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2011;9:881–90. PubMed

Miehlke S, Madisch A, Voss C, et al. . Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005;22:1115–19. PubMed

Miehlke S, Hansen JB, Madisch A, et al. . Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. Inflamm Bowel Dis 2013;19:2763–7. PubMed

Hjortswang H, Tysk C, Bohr J, et al. . Defining clinical criteria for remission and disease activity in collagenous colitis. Inflamm Bowel Dis 2009;15:1875–81. PubMed

Hjortswang H, Jarnerot G, Curman B, et al. . The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 2006;41: 1196–203. PubMed

Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J eds. Assessment of quality of life in clinical trials of cardiovascular therapies. Washington, DC, USA: Le Jacq Publishing Inc., 1984:170–83.

Stjernman H, Grännö C, Järnerot G, et al. . Short Health Scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn's disease. Inflamm Bowel Dis 2008;14:47–52. PubMed

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort

. 2019 Sep ; 10 (9) : e00071.

Zobrazit více v PubMed

EudraCT
2007-001315-31

ClinicalTrials.gov
NCT01278082

Najít záznam

Citační ukazatele

Možnosti archivace